Loading...
XSTOSUS
Market cap734mUSD
Dec 23, Last price  
159.10SEK
1D
-1.49%
1Q
28.10%
IPO
1,320.54%
Name

Surgical Science Sweden AB

Chart & Performance

D1W1MN
XSTO:SUS chart
P/E
34.70
P/S
9.20
EPS
4.59
Div Yield, %
0.00%
Shrs. gr., 5y
15.60%
Rev. gr., 5y
68.14%
Revenues
883m
+10.01%
41,103,21446,100,00051,800,00057,976,00065,700,000101,515,000104,799,000366,778,000802,540,000882,853,000
Net income
234m
+24.47%
-3,036,8581,600,0003,300,000-2,258,000-4,519,00012,598,00015,606,00086,248,000187,974,000233,972,000
CFO
238m
+84.03%
07,500,00013,400,0007,937,0006,878,00055,202,00023,225,00039,083,000129,487,000238,291,000
Earnings
Feb 19, 2025

Profile

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.
URL
https://surgicalscience.com/
IPO date
Jun 19, 2017
Employees
259
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
882,853
10.01%
802,540
118.81%
366,778
249.98%
Cost of revenue
691,642
645,684
312,503
Unusual Expense (Income)
NOPBT
191,211
156,856
54,275
NOPBT Margin
21.66%
19.54%
14.80%
Operating Taxes
34,292
20,199
(20,444)
Tax Rate
17.93%
12.88%
NOPAT
156,919
136,657
74,719
Net income
233,972
24.47%
187,974
117.95%
86,248
452.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
19,148
3,039,053
BB yield
Debt
Debt current
15,079
12,793
Long-term debt
80,046
29,364
24,142
Deferred revenue
20,288
Other long-term liabilities
17,209
41,015
100,105
Net debt
(559,090)
(393,657)
(284,711)
Cash flow
Cash from operating activities
238,291
129,487
39,083
CAPEX
(10,456)
(34,548)
(14,377)
Cash from investing activities
(44,129)
(34,548)
(2,732,614)
Cash from financing activities
15,847
17,093
2,922,463
FCF
80,551
102,528
(16,973)
Balance
Cash
634,366
433,733
316,680
Long term investments
4,770
4,367
4,966
Excess cash
594,993
397,973
303,307
Stockholders' equity
947,091
857,466
206,089
Invested Capital
3,827,739
3,895,357
3,498,469
ROIC
4.06%
3.70%
3.81%
ROCE
4.28%
3.61%
1.45%
EV
Common stock shares outstanding
50,941
50,914
42,669
Price
Market cap
EV
EBITDA
246,824
208,441
87,792
EV/EBITDA
Interest
656
1,305
22,947
Interest/NOPBT
0.34%
0.83%
42.28%